News | February 10, 2008

Medrad, Possis Medical Sign $361 Million Merger Agreement

February 11, 2008 – Medrad Inc. today said it entered into a definitive merger agreement to acquire Possis Medical Inc., which in combination will offer a broader, more comprehensive suite of products to the cardiovascular intervention field.

The cash tender offer is for $19.50 per share, or a total equity value of approximately $361 million. The offer price represents a premium of approximately 39 percent over Possis Medical’s average closing price for the 30 days prior to Feb. 8, 2008. The Possis Medical Board of Directors unanimously approved the transaction and will recommend the offer to its shareholders. The parties agreed to commence within the next 10 business days followed by a merger.

Medrad is a provider of contrast injection systems used to diagnose cardiovascular and other diseases. Possis Medical is a provider of mechanical thrombectomy devices used to treat narrowed or blocked arteries and veins.

Medrad says the combination of the two compatible sales organizations and shared target customer groups establishes an expansive footprint in the cardiovascular intervention field. Medrad’s broad international distribution infrastructure offers a platform for the expansion of Possis Medical’s product portfolio into largely underpenetrated international markets. The companies say the combination of Possis Medical’s thrombectomy platform and Medrad’s vascular injection systems offers a complimentary focus on high-pressure intravascular fluid management and represents a broadened base for future development of new and innovative applications.

Headquartered near Minneapolis, Possis Medical last year posted revenues of $67 million and employs approximately 280 people. Unveiled in 1997, Possis Medical’s AngioJet Rheolytic Thrombectomy System is a leading mechanical thrombectomy system. More than 300,000 patients worldwide have been treated with AngioJet therapy. Possis Medical recently launched the AngioJet Ultra System, a new easier-to-use drive unit.

For more information:

Related Content

ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Technology | Pulmonary Embolism| March 01, 2017
March 1, 2017 — BTG plc announced U.S.
global thrombectomy devices market, Allied Market Research report, 2022
News | Thrombectomy Devices| January 05, 2017
January 5, 2017 — A new report published by Allied Market Research forecasts that the global...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Penumbra System, ACE68 Reperfusion Catheter, thrombectomy device, SNIS 2016, acute ischemic stroke patients
Technology | Thrombectomy Devices| July 27, 2016
July 27, 2016 — Penumbra Inc. announced U.S.
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
Pulmonary embolism, toshiba

A pulmonary embolism visualized on a CTA scan using SureSubtraction software on a Toshiba Aquilion One Vision CT scanner. 

Feature | Pulmonary Embolism| March 28, 2016 | Alain T. Drooz, M.D., FSVM, and David J. Spinosa, M.D.
Acute pulmonary embolism (PE) can pose a major treatment quandary for clinicians.
SITS Open trial, mechanical thrombectomy devices. pREset, stroke treatment
News | Thrombectomy Devices| March 08, 2016
March 8, 2016 — phenox GmbH announced participation in the SITS Open clinical trial, where pREset and pREset LITE ...
Overlay Init